Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of... (he American Foundation for AgingResearch...)

Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors

Date:7/1/2008

he American Foundation for Aging Research, The Gladstone Institute of Neurological Disease at The University of California Medical School, and The Center for Neurodegenerative Disease at Brigham and Women's Hospital to name a few. Dr. Goldberg has published nearly 400 scientific articles and is an inventor on numerous patents.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for diseases that affect the central nervous system. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from http://www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-look
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine news :

1. Repligen Announces Share Repurchase Program
2. Repligen Announces Conference Call to Update Orencia(R) Lawsuit
3. Repligen Elects Earl Henry, M.D. to the Board of Directors
4. Repligen to Present at Upcoming Healthcare Conferences Wednesday, November 28th and Wednesday, December 5th
5. Repligen Reports Second Quarter Fiscal Year 2008 Financial Results
6. East Jefferson General Hospital Selects Allscripts Electronic Health Record, Offers Free Electronic Prescribing for Affiliated New Orleans-Area Physicians
7. The University of Toledo selects SXC Health Solutions (informedRx) to provide pharmacy benefit management services
8. Michigan Health & Hospital Association Elects 2008 Officers and Board Members, Bestows Awards
9. Hoag Memorial Hospital Presbyterian Selects Allscripts for Electronic Health Record Subsidy Program
10. District of Columbia Primary Care Association Selects Microsoft Amalga to Improve Patient Care for the Underserved
11. Martin Memorial Health Systems Selects Allscripts for Electronic Health Record and Practice Management

Post Your Comments:

(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) -- ... to impossible, but a new study adds to a ... CT scans may help spot the beginnings of disease ... the greatest risk for lung cancer, 6 percent were ... and follow-up biopsies to confirm the diagnosis. CT scans ...

(Date:5/21/2013)... Sunnyvale, California (PRWEB) May 21, 2013 ... invites individuals who are grieving to remember and honor ... an Evening of Remembrance Memorial Service, Sunday, June 2, ... at Skyline Boulevard, San Mateo, CA 94402. , ... non-denominational, and includes a short program with music, readings ...

(Date:5/21/2013)... Calif. (PRWEB) May 21, 2013 Not ... a dual diagnosis of Borderline Personality Disorder (BPD) and ... is proving to be successful for the treatment of ... 1, Alina Gorgorian, Ph.D., clinical director of Clearview ... in Los Angeles, will provide attendees of the West ...

(Date:5/21/2013)... more likely than their normal-weight counterparts to repeatedly ... continuity of care and leads to more emergency ... The practice of "doctor shopping" among overweight patients ... the health care system, whether that be off-putting ... by providers, or improperly sized medical equipment and ...

(Date:5/21/2013)... N.C. An attack on glioblastoma brain tumor cells ... in an early study to establish the proper dose ... treatment, developed at Duke and tested in an ongoing ... cells have an abundance of receptors that work like ... the cells. , The investigational therapy, known as ...

Breaking Medicine News(10 mins):Health News:Study Supports Using Low-Dose CT Scans to Spot Early Lung Cancer 2 Health News:Study Supports Using Low-Dose CT Scans to Spot Early Lung Cancer 3 Health News:Hospice Offers Evening of Remembrance Memorial Service in San Mateo, California 2 Health News:Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD 2 Health News:Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD 3 Health News:'Doctor shopping' by obese patients negatively affects health 2 Health News:'Doctor shopping' by obese patients negatively affects health 3 Health News:Poliovirus vaccine trial shows early promise for recurrent glioblastoma 2

[0] Study Supports Using Low-Dose CT Scans to Spot Early Lung Cancer [0] Hospice Offers Evening of Remembrance Memorial Service in San Mateo, California [0] Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD [0] 'Doctor shopping' by obese patients negatively affects health [0] Poliovirus vaccine trial shows early promise for recurrent glioblastoma

... makers debate what levels of ozone in the air are ... that the inhaled pollutant impairs the bodys first line of ... as bacteria. , While it has long been known ... pollution, is associated with increased cardiovascular and pulmonary hospitalizations and ...

... Programs in ... Need, BUDAPEST, Hungary, Sept. 29 With more ... each year, it has never,been more critical to increase ... the U.S.-Middle East Partnership for,Breast Cancer Awareness and Research, ...

... finds 123 deaths linked to the products since 1969 ... experts on Friday urged the federal Food and Drug ... and cold medicines for young children. , The recommendation, ... in children under 2, and antihistamines in those younger ...

... MCLEAN, Va., Sept. 28 Sunrise Senior Living,Inc. ... on the status of the independent,investigation being conducted ... Directors, provided an update on management,s Sarbanes-Oxley,Section 404 ... on legal,proceedings. Special Independent Committee Investigation ...

... a,statement by ADA President Kathleen Roth, DDS, on ... Bill: "The American Dental Association applauds the ... in legislation reauthorizing,the State Children,s Health Insurance Program. ... care that they need to enjoy good,oral health. ...

... Medical today announced a,partnership with leading breast care ... including breast care physicians from,Connecticut to California, will ... and availability of an innovative, non-surgical,treatment option for ... will host a gathering of these new Centers ...

Ozone shuts down early immune response in lungs and body Susan G. Komen for the Cure Launches Unprecedented Global Expansion Program in 10 Countries FDA Advisers Urge Ban on Cold Medicines for Young Children Sunrise Provides Status Report on Special Independent Committee Investigation; Provides Updates on Management's Internal Control Review Efforts and on Legal Proceedings Statement by ADA President Kathleen Roth, DDS, on the Inclusion of Stable Dental Benefit in SCHIP Reauthorization Bill Sanarus Announces Partnership With Leading US Breast Care Physicians for the Next Generation Visica 2(TM) Treatment System for Fibroadenomas

(Date:5/21/2013)... PARIS and TARRYTOWN, N.Y. ... and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) ... Medicine published online the positive Phase 2a study ... asthma. Dupilumab is an investigational monoclonal antibody targeting the ... which modulates signaling of both IL-4 and IL-13, drivers ...

(Date:5/21/2013)... U.S. spending on specialty prescription drugs — ... cancer, multiple sclerosis and rheumatoid arthritis — is projected ... according to a forecast released today by Express Scripts ... "As we see what,s on the ... act so they can continue to offer an affordable ...

(Date:5/21/2013)... , May 21, 2013 AcelRx ... a specialty pharmaceutical company focused on the ... the treatment of acute and breakthrough pain, ... a placebo-controlled Phase 3 study of its ... System (NanoTab System), the primary efficacy endpoint ...

Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7 U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2 U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3 U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4 U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5 Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2 Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3 Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4 Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5 Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6 Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7 Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8 Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9 Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10

[0] Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine [0] U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 [0] Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain

... Fla., Oct. 11, 2011 PediaVision announced today that ... United States to increase their efficiency and income through ... screening device that will help redefine the pediatric office ... pediatrics center in New Jersey, is a model of ...

... Heart disease is an ever-present threat in the family of ... experienced a heart attack in her early fifties. That,s why the ... Aspirin and WomenHeart: The National Coalition for Women with Heart ... Health to get women talking to each other and their ...

Cached Medicine Technology:Spot Helps Redefine the Pediatric Office of the Future 2 Spot Helps Redefine the Pediatric Office of the Future 3 Joy & Eve Behar Launch Bilingual Heart Health Guide Inspired By Women Heart Attack Survivors and Caregivers 2 Joy & Eve Behar Launch Bilingual Heart Health Guide Inspired By Women Heart Attack Survivors and Caregivers 3 Joy & Eve Behar Launch Bilingual Heart Health Guide Inspired By Women Heart Attack Survivors and Caregivers 4 Joy & Eve Behar Launch Bilingual Heart Health Guide Inspired By Women Heart Attack Survivors and Caregivers 5 Joy & Eve Behar Launch Bilingual Heart Health Guide Inspired By Women Heart Attack Survivors and Caregivers 6

Spot Helps Redefine the Pediatric Office of the Future Joy & Eve Behar Launch Bilingual Heart Health Guide Inspired By Women Heart Attack Survivors and Caregivers

... 105SL combines enhanced memory, processing ... and reliable all-metal construction. Proven ... and print speed make it ... who value reliability, productivity, consistent ...

... Built on the solid, tested ... six-inch labels --offers an unprecedented level ... placement as well as unique features ... into enterprise systems, automatic calibration, flexible ...

... The 220XiIII quickly prints labels ... at 10 ips. It is ... such as printing chemical drum ... automotive industry labels, banner-sized labels ...

... The 140XiIII is the fastest ... Series. With such powerful performance and ... choice for high-volume, mission-critical applications with ... also well-suited for applications in which ...

Medicine Products:

105SL R170Xi Zebra Printer 220xiIII Zebra 140xiIII Barcode Printer